Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-95475939 for moderate to severe atopic dermatitis
ISRCTN16314965Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of JNJ-95475939 in atopic dermatitis (AD), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with EASI-75 response at Week 12. Started Feb 2025; status: completed.
02
Drugs
JNJ-95475939
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ISRCTN16314965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16314965.